Tepmetko 225mg Tablet is a medication that contains Tepotinib as an active agent. The primary benefit of this medication is its ability to slow down or stop the growth and prevent the spread of cancer cells in the body, particularly in patients with non-small cell lung cancer (NSCLC) that has a mutation in the MET gene (surface of certain cancer cells). Another potential benefit of Tepmetko 225mg Tablet is that it may have fewer side effects when compared to traditional chemotherapy. However, it can still cause side effects like nausea, vomiting, and fatigue. Patients who are allergic to Tepmetko 225mg Tablet or its components should not use this medication. 

Patients with previous heart, kidney, lung, and liver disease should talk to a doctor before taking this medication. This medicine has not been studied in elderly patients, so its use in this population requires careful monitoring. Patients receiving it are monitored for signs of bleeding, such as hemoptysis (coughing up blood), melena (dark, tarry stools), or hemorrhagic shock. It is recommended to avoid consuming large amounts of grapefruit or grapefruit juice, as it can increase the risk of adverse reactions or interactions with some medications.

• Treatment of non-small cell lung cancer (NSCLC)

In patients with NSCLC and the specific MET mutation, Tepmetko 225mg Tablet has been shown to have an anti-tumor effect, leading to tumor shrinkage and improved disease control. Studies have demonstrated that this medicine can significantly improve progression-free survival (PFS) in patients with NSCLC compared to standard chemotherapy.

Inform your healthcare provider about all your medicines, including prescription, over-the-counter, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Tepmetko 225mg Tablet, reducing effectiveness by causing undesirable side effects.

• Store in a refrigerator between 20-25°C (68-77°F).
• Keep away from moisture, heat, and light.
• It should not be frozen.
• Keep it in its original packaging until it is ready to be used.
• Keep out of the reach of children and pets.

Take Tepmetko 225mg Tablet exactly as your doctor prescribes. The recommended dose and dosing schedule may vary depending on your medical condition, age, weight, and other factors. It should be taken with food. Swallow the tablet as a whole with a glass of water. Patients should not chew, crush, or break the tablet, as this may affect the effectiveness of the medication. Avoid doubling the dose to compensate for the missed dose.

Tepmetko 225mg Tablet cause some side effects like all medications, although not everyone will experience them. 

Serious:

• Hepatotoxicity
• Interstitial lung disease (ILD)
• Severe skin reactions
• Perforation or fistula formation in the gastrointestinal tract
• Bleeding, including severe or fatal bleeding

Common:

• Edema (swelling)
• Nausea
• Diarrhea
• Fatigue
• Anorexia (loss of appetite)
• Vomiting
• Increased blood creatinine levels
• Increased alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels
• Rash or itching
• Muscle pain or weakness

If you have been prescribed Tepmetko 225mg Tablet, it is important to follow your doctor's instructions carefully. Suppose you experience any unusual symptoms or side effects while taking Tepmetko 225mg Tablet, such as fever, persistent cough, difficulty breathing, abdominal pain, or signs of liver dysfunction. In such a case, you should contact your doctor immediately. Do not stop medication without first consulting your doctor, as this may affect the effectiveness of the medication and your treatment outcomes. Pregnant and breastfeeding women should consult with a healthcare provider before taking it. Avoid close contact with an infected person, as this medication lowers the immune system. Always maintain a healthy and balanced diet to support your overall health and well-being.

1. Merck Limited, Electronic Medicines Compendium (EMC), [Revised on 25 May 2022] [Accessed on 10th May 2023], https://www.medicines.org.uk/emc/product/12970/smpc 
2. EMD Serono, Inc., US Food & Drug Administration, [Revised on 3rd Feb 2021] [Accessed on 10th May 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214096s000lbl.pdf
3. Goodman & Gilman's the pharmacological basis of Therapeutics, 13th Edition., 2018, 1549-1674